Targeting Toll-Like Receptors for Cancer TherapySpringer Science and Business Media LLC - Tập 13 - Trang 583-598 - 2018
Marc J. Braunstein, John Kucharczyk, Sylvia Adams
The immune system encompasses a broad array of defense mechanisms against foreign threats, including invading pathogens and transformed neoplastic cells. Toll-like receptors (TLRs) are critically involved in innate immunity, serving as pattern recognition receptors whose stimulation leads to additional innate and adaptive immune responses. Malignant cells exploit the natural immunomodulatory funct...... hiện toàn bộ
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer PatientsSpringer Science and Business Media LLC - Tập 12 - Trang 341-351 - 2017
Yuji Mishima, Satoshi Matsusaka, Keisho Chin, Mariko Mikuniya, Sayuri Minowa, Tomoko Takayama, Harumi Shibata, Ryoko Kuniyoshi, Mariko Ogura, Yasuhito Terui, Nobuyuki Mizunuma, Kiyohiko Hatake
A key to the successful use of targeted cancer therapy is the ability to preselect patients who are likely to benefit from the treatment according to molecular markers. Assessment for predicting therapy response is mostly done using tumor biopsies. However, these might not truly represent all of the patient’s malignant cells because of tumor heterogeneity and/or clonal evolution during disease pro...... hiện toàn bộ
Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinibSpringer Science and Business Media LLC - - 2006
Yuji Mishima, Yasuhito Terui, Kengo Takeuchi, Eijiro Nagasaki, Masahiro Yokoyama, Nobuyuki Mizunuma, Shunji Takahashi, Katsushi Yamada, Tetsu Fukunaga, Junji Yamamoto, T. Yamaguchi, Yukio Kato, Kiyohiko Hatake
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation TrialSpringer Science and Business Media LLC - Tập 16 - Trang 47-57 - 2020
Céleste Lebbé, Antoine Italiano, Nadine Houédé, Ahmad Awada, Philippe Aftimos, Thierry Lesimple, Monica Dinulescu, Jan H. M. Schellens, Suzanne Leijen, Sylvie Rottey, Vibeke Kruse, Richard Kefford, Eric Raymond, Sandrine Faivre, Celine Pages, Carlos Gomez-Roca, Armin Schueler, Samantha Goodstal, Giorgio Massimini, Jean-Pierre Delord
Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in a cohort of patients with locally advanced/metastatic melanoma from a first-in-human study of pimasertib. This was a phase I, open-label, two-part, dose-escalation study. Pa...... hiện toàn bộ